The Price of Biosimilars

Article

Part II of a series on these new agents

As noted in part I, a biosimilar is a biological product that is “biosimilar” to or “interchangeable” with an FDA-licensed biological product. These agents have been available in Europe for several years but are not yet available in the U.S. On 1/7/15, a 14-member expert panel unanimously recommended that the FDA approves EP2006, which is a close copy of filgrastim (Neupogen). EP2006 was approved in Europe in 2009 as Zarzio but has not been used in the U.S., in part because no regulatory pathway exists to approve biosimilars in the U.S.

If the FDA accepts the panel’s recommendation, it would open the door for producing biosimilars in the U.S., which are typically less expensive than the already-approved biologic agents. The savings in drug costs would be significant. According to the New York Times, Express Scripts notes biosimilars are about a third less expensive than brand-name biologic drugs in countries where they are in use and the cost savings may be significant for both the insurer as well as the patient.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a man with a beard in front of a blue background
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background